How many employees does Mesoblast have this year?
Mesoblast has 83 undefined employees this year.
Mesoblast Employees 2025
Mesoblast Employees
83
Ticker
MSB.AX
ISIN
AU000000MSB8
WKN
A0DNPW
In 2025, Mesoblast employed 83 people, a 0% change from the 83 number of employees in the previous year.
Mesoblast Aktienanalyse
What does Mesoblast do?
Mesoblast Ltd is an Australian biotechnology company specializing in the development and production of novel cell-based therapies for serious diseases. The company was founded in 2004 as a spin-off of the Australian Monash University. Mesoblast's business model is based on the development of cell-based therapies using mesenchymal stem cells (MSCs). The company has specialized in researching MSCs and holds patents for their use in various medical fields. Mesoblast has developed an innovative technology platform to produce MSCs on a large scale and ensure high activity and quality of their products. Mesoblast has three different divisions covering different areas of medicine. The first division focuses on cardiovascular diseases and researches MSC-based therapies for patients with heart conditions such as heart attack or heart failure. The company has already conducted clinical trials with positive results. The second division focuses on orthopedics and spine, aiming to improve the regeneration of poorly healing bone fractures or chronic back problems. Mesoblast has also conducted clinical trials in this area with positive results. The third division focuses on immunology and inflammation, aiming to develop therapeutic applications that regulate inflammatory reactions in the body. These therapies could be used, for example, in autoimmune diseases. Mesoblast offers various products based on the use of MSCs. One of the main products is Temcell, a therapy used to treat graft-versus-host disease (GvHD). GvHD is a life-threatening complication that can occur after a stem cell transplant. Temcell aims to modulate the patient's immune system and alleviate the symptoms of GvHD. Another product of Mesoblast is Revascor, an intravenous infusion used to treat patients with severe heart failure. Revascor contains live MSCs that are intended to promote heart muscle regeneration and improve heart function. Mesoblast is an innovative company specializing in the development of cell-based therapies. The company has already achieved notable successes and is expected to continue bringing groundbreaking products to the market in the future. Mesoblast ist eines der beliebtesten Unternehmen auf Eulerpool.com.Employees Details
Examining Mesoblast's Employee Base
Mesoblast's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Mesoblast's operational capacity and future potential.
Year-to-Year Comparison
Assessing Mesoblast's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.
Impact on Investments
Mesoblast's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.
Interpreting Employee Trends
Fluctuations in Mesoblast’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.
Frequently Asked Questions about Mesoblast stock
How many employees did Mesoblast have compared to the previous year?
Compared to the previous year, Mesoblast had 0% more employees.
What impact did the number of employees have on the company Mesoblast?
The number of employees has a direct impact on the efficiency and productivity of Mesoblast. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.
What impact did the number of employees have on investors of Mesoblast?
The number of employees can also have an impact on investors of Mesoblast, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.
How does an increase in equity capital of Mesoblast affect the company?
An increase in equity of Mesoblast can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.
How does a reduction in Mesoblast's equity affect the company?
A reduction in equity of Mesoblast can impair its financial stability and decrease its ability to fulfill future investments and obligations.
What are some factors that influence the equity of Mesoblast?
Some factors that can influence the equity of Mesoblast include, among others, revenue development, profit and loss statement, dividend payments, and investments.
Why is the equity of Mesoblast so important for investors?
The equity of Mesoblast is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.
How does the number of employees at Mesoblast influence the company?
The number of employees at Mesoblast can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.
How has the number of employees at Mesoblast evolved in recent years?
In recent years, the number of employees at Mesoblast has changed by 0.
How many employees does Mesoblast currently have?
Mesoblast currently has 83 undefined employees.
Why is the number of employees important for investors of Mesoblast?
The number of employees is important for investors of Mesoblast as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.
What strategic measures can Mesoblast take to change the number of employees?
To change the number of employees, Mesoblast can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.
How much dividend does Mesoblast pay?
Over the past 12 months, Mesoblast paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Mesoblast is expected to pay a dividend of 0 USD.
What is the dividend yield of Mesoblast?
The current dividend yield of Mesoblast is .
When does Mesoblast pay dividends?
Mesoblast pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Mesoblast?
Mesoblast paid dividends every year for the past 0 years.
What is the dividend of Mesoblast?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Mesoblast located?
Mesoblast is assigned to the 'Health' sector.
Wann musste ich die Aktien von Mesoblast kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Mesoblast from 10/20/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/20/2025.
When did Mesoblast pay the last dividend?
The last dividend was paid out on 10/20/2025.
What was the dividend of Mesoblast in the year 2024?
In the year 2024, Mesoblast distributed 0 USD as dividends.
In which currency does Mesoblast pay out the dividend?
The dividends of Mesoblast are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Mesoblast
Our stock analysis for Mesoblast Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Mesoblast Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
